Meropenem Puren (Meropenem)

Meropenem works by binding to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final steps of peptidoglycan synthesis. This disruption weakens the cell wall, leading to bacterial lysis and death. Its broad spectrum covers many Gram‑negative, Gram‑positive and anaerobic pathogens.

The dosage of Meropenem Puren is determined by the prescribing clinician based on the type and severity of infection, the patient’s renal function, age and weight. Dosing regimens are individualized and should follow local clinical guidelines and the product’s prescribing information.

Safety data for Meropenem in pregnancy are limited, and the drug is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any potential risk to the fetus. Caution is also advised during breastfeeding, as the drug may be excreted in milk.

To order Meropenem Puren, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Meropenem shares a similar spectrum and mechanism with other carbapenems such as imipenem and ertapenem, but it offers a broader activity against certain resistant Gram‑negative organisms and has a lower propensity for inducing seizures compared with imipenem. Choice of agent depends on local resistance patterns and patient‑specific factors.

Meropenem Puren should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and do not freeze or shake the solution. Proper cold‑chain handling is essential to maintain drug stability.

Meropenem Puren is supplied as a sterile powder for injection and is reconstituted with a suitable diluent. The solution is administered intravenously, typically over 15‑30 minutes, under the supervision of qualified healthcare professionals in a clinical setting.

Serious risks include severe allergic reactions such as anaphylaxis, seizures (particularly in patients with renal impairment or pre‑existing CNS disorders), Clostridioides difficile‑associated colitis, and acute kidney injury. Prompt recognition and management of these events are critical.

Meropenem Puren should be avoided in patients with a known hypersensitivity to carbapenems, other beta‑lactam antibiotics, or any component of the formulation. Caution is also required for patients with severe renal impairment, a history of seizures, or those receiving valproic acid.